Skip to content
RKWD
ROCKWOOD RESEARCH · A CORPORATE FILINGS WEBSITE|STRAIGHT FROM THE SOURCE · SEC EDGAR|SPONSOREDYour message on this tape — bid on the Rockwood Ad Exchange · Rockwood Ad Exchange|
Rockwood Research
…

TNGX

Tango Therapeutics, Inc.

Pharmaceutical Preparations · SIC 2834CIK 1819133Held by 6 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:XLINKEDINEMAIL
Revenue FY2025
$62.0M
Net Income FY2025
$(102.0M)
EPS (Basic, as reported)
$-0.87
Net Margin FY2025
-162.9%
ROE FY2025
-29.3%
Total Equity
$346.0M
Shares Out
169M
Business description

Tango Therapeutics, Inc. — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2020–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions
i
default rows · click any row to chart itRevenue: 8 → 62 +50.6% CAGR
Fiscal yearFY2020FY2021⚑FY2022FY2023FY2024FY2025
Revenue83725374262
Research & development(50)(78)(106)(115)(144)(132)
General & administrative(10)(18)(30)(36)(44)(42)
Total operating expenses(60)(95)(136)(151)(188)(174)
Operating income(52)(58)(111)(114)(146)(111)
Other income (expense), net003131610
Pre-tax income(52)(58)(108)(102)(130)(102)
Income tax expense000000
Net income(52)(58)(108)(102)(130)(102)
EPS — basic—($0.94)($1.23)($1.08)($1.19)($0.87)
EPS — diluted—($0.94)($1.23)($1.08)($1.19)($0.87)
Shares outstanding — basic (M)—628895109116
Shares outstanding — diluted (M)—628895109116
  • ⚑ Weighted-average shares changed ×1.42 between FY2021 and FY2022 — a large issuance or reduction. Per-share figures on either side are as reported and not adjusted.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.